(MNPR) Monopar Therapeutics - Performance 679.5% in 12m
MNPR performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-2.36%
#41 in Peer-Group
Rel. Strength
99.63%
#29 in Stock-Universe
Total Return 12m
679.53%
#2 in Peer-Group
Total Return 5y
-18.49%
#42 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 51.89 USD |
| 52 Week Low | 2.21 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 19.89 |
| Buy/Sell Signal +-5 | -0.47 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: MNPR (679.5%) vs XBI (-7.6%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
10.4% | 76.6% | 81.6% | 23 | 13.8 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-6.77% | -4.62% | 149% | 12.9 | 12 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
9.62% | 0.48% | 57% | 26.8 | 13.9 | 0.97 | 0.60% | 41% |
| BIM PA Biomerieux |
2.27% | 33.8% | 9.65% | 32.6 | 25.6 | 1.54 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
3.43% | -8.06% | 7.86% | 42.4 | 24.4 | 0.27 | 18.7% | -34.3% |
| PTCT NASDAQ PTC Therapeutics |
13.1% | 44.8% | 4.12% | 7.86 | 6.36 | 0.81 | - | 68% |
| KMDA NASDAQ Kamada |
0.29% | 36.9% | -12% | 24.6 | 20.4 | 0.81 | 48.1% | 3.93% |
| ERF PA Eurofins Scientific SE |
8.57% | 17.2% | 11.2% | 28.9 | 15.1 | 0.63 | -62.1% | -19.3% |
Performance Comparison: MNPR vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for MNPR
| Total Return (including Dividends) | MNPR | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -15.25% | 7.76% | 1.11% |
| 3 Months | -2.07% | -5.31% | 5.58% |
| 12 Months | 679.53% | -7.58% | 10.51% |
| 5 Years | -18.49% | -18.55% | 109.12% |
| Trend Score (consistency of price movement) | MNPR | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -43.7% | 84.2% | 69.9% |
| 3 Months | -24.2% | -2.8% | 69.3% |
| 12 Months | 88.5% | -77.8% | 43.2% |
| 5 Years | -42.6% | -53.5% | 84.1% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | #188 | -21.35% | -16.17% |
| 3 Month | #89 | 3.41% | -7.25% |
| 12 Month | #3 | 743.46% | 605.40% |
| 5 Years | #44 | 0.07% | -61.02% |
FAQs
Does Monopar Therapeutics (MNPR) outperform the market?
Yes,
over the last 12 months MNPR made 679.53%, while its related Sector, the SPDR S&P Biotech (XBI) made -7.58%.
Over the last 3 months MNPR made -2.07%, while XBI made -5.31%.
Performance Comparison MNPR vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
MNPR vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -2.8% | -16.4% | 26.5% | 669% |
| US NASDAQ 100 | QQQ | -2.5% | -16.7% | 27.3% | 670% |
| German DAX 40 | DAX | -0.6% | -14.5% | 10.2% | 650% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -2.5% | -14.3% | 24.7% | 668% |
| Hongkong Hang Seng | HSI | -3.3% | -20.3% | 7.5% | 652% |
| India NIFTY 50 | INDA | -1% | -13.9% | 27.6% | 681% |
| Brasil Bovespa | EWZ | -5.1% | -15.7% | 6.3% | 670% |
MNPR vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -2.4% | -16.7% | 23.7% | 657% |
| Consumer Discretionary | XLY | -2.2% | -13.5% | 36.4% | 662% |
| Consumer Staples | XLP | -2.5% | -15% | 25.1% | 673% |
| Energy | XLE | -8.6% | -18.2% | 22.9% | 676% |
| Financial | XLF | -1.2% | -12.7% | 23.7% | 656% |
| Health Care | XLV | -4.7% | -19.6% | 27% | 685% |
| Industrial | XLI | -1.7% | -15.6% | 21% | 661% |
| Materials | XLB | -2.1% | -16.7% | 25.8% | 680% |
| Real Estate | XLRE | -3.3% | -16.2% | 25.5% | 666% |
| Technology | XLK | -3.1% | -17.3% | 26.1% | 675% |
| Utilities | XLU | -4.1% | -15.8% | 18.2% | 658% |
| Aerospace & Defense | XAR | -1.8% | -21% | 9.6% | 637% |
| Biotech | XBI | -2.4% | -23% | 37.3% | 687% |
| Homebuilder | XHB | -1.2% | -10.2% | 42% | 689% |
| Retail | XRT | 1.2% | -15.1% | 34.5% | 679% |
MNPR vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | -14.6% | -33.9% | 16.7% | 676% |
| Natural Gas | UNG | -2% | -12.6% | 8.3% | 694% |
| Gold | GLD | -6.4% | -21.4% | -3.6% | 632% |
| Silver | SLV | -2% | -26.6% | 6.9% | 657% |
| Copper | CPER | -0.2% | -17% | 11.7% | 671% |
MNPR vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | -4.3% | -15.9% | 28% | 684% |
| iShares High Yield Corp. Bond | HYG | -3.2% | -15.8% | 22.9% | 670% |